What type of medicine is Fruquintinib?

Fruquintinib (Fruquintinib) is an oral small molecule targeted therapy drug that belongs to a class of multicaseokinase inhibitors. This type of drug mainly affects cell signaling by inhibiting polytyrosine kinase (tyrosine kinase), thereby blocking the growth and spread of cancer cells.

Specifically, fruquintinib mainly acts on vascular endothelial growth factor receptors (VEGFR), which include VEGFR-1, VEGFR-2 and VEGFR-3. These receptors play a key role in regulating the process of angiogenesis, a process in which tumor growth is often accompanied by the need for new blood vessels so that the tumor can obtain sufficient oxygen and nutrients.

By inhibiting the activity ofVEGFR, fruquintinib can interfere with the angiogenesis process and reduce the tumor's dependence on blood supply, thus inhibiting the growth and spread of tumors. This makes fruquintinib an anti-angiogenic drug, particularly showing potential efficacy in the treatment of cancers such as advanced gastric cancer and colorectal cancer.

It should be noted that fruquintinib is often used as part of maintenance therapy, aiming to control disease progression and prolong patient survival. Compared with traditional chemotherapy drugs, targeted therapy drugs such as fruquintinib are more specific and can reduce some common side effects.

However, like all drugs, fruquintinib may cause some adverse reactions, including high blood pressure, hand-foot syndrome, etc. Therefore, when using fruquintinib, patients need to be monitored and guided by their doctors to ensure the best therapeutic effect and reduce potential risks.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.